ALUNBRIG Approved by European Commission as Treatment for Patients with ALK+ NSCLC
kalhh / Pixabay

ALUNBRIG Approved by European Commission as Treatment for Patients with ALK+ NSCLC

  According to a release on Biospace, the European Commission (EC) has approved Takeda Pharmaceutical's ALUNBRIG (brigatinib) as treatment for patients with anaplastic lymphoma kinase-positive (ALK+) advanced non-small cell lung cancer…

Continue Reading ALUNBRIG Approved by European Commission as Treatment for Patients with ALK+ NSCLC

How This Family is Raising Awareness for Progressive Familial Intrahepatic Cholestasis

Shannon and Todd Palmatier have three children, two of which have progressive familial intrahepatic cholestasis (PFIC). Their sons' diagnoses have brought the lack of knowledge and advocacy to the attention…

Continue Reading How This Family is Raising Awareness for Progressive Familial Intrahepatic Cholestasis